Targeting regulatory T cells (Q37983467)

26 August 2017

Targeting regulatory T cells (English)

1 reference

26 August 2017

Christine Ménétrier-Caux

1

1 reference

26 August 2017

Tyler Curiel

2

1 reference

26 August 2017

Julien Faget

3

1 reference

26 August 2017

Manuarii Manuel

4

1 reference

26 August 2017

Christophe Caux

5

1 reference

26 August 2017

Weiping Zou

6

1 reference

26 August 2017

12 February 2012

1 reference

26 August 2017

1 reference

26 August 2017

7

1 reference

26 August 2017

1

1 reference

26 August 2017

15-28

1 reference

https://scigraph.springernature.com/pub.10.1007/s11523-012-0208-y

26 August 2017

0 references

cites work

Control of regulatory T cell development by the transcription factor Foxp3

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Interleukin-10-secreting type 1 regulatory T cells in rodents and humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

FOXP3 defines regulatory T cells in human tumor and autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

IL-17+ regulatory T cells in the microenvironments of chronic inflammation and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Identification of T helper type 1-like, Foxp3+ regulatory T cells in human autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Differential expression of CTLA-4 among T cell subsets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Co-expression of TNFR2 and CD25 identifies more of the functional CD4+FOXP3+ regulatory T cells in human peripheral blood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Phenotype, localization, and mechanism of suppression of CD4(+)CD25(+) human thymocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Foxp3-dependent and -independent molecules specific for CD25+CD4+ natural regulatory T cells revealed by DNA microarray analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Role of LAG-3 in regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Selective expression of latency-associated peptide (LAP) and IL-1 receptor type I/II (CD121a/CD121b) on activated human FOXP3+ regulatory T cells allows for their purification from expansion cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Latency-associated peptide identifies a novel CD4+CD25+ regulatory T cell subset with TGFbeta-mediated function and enhanced suppression of experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

The Tregs' world according to GARP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Perspectives on Regulatory T Cell Therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Identification of a regulatory T cell specific cell surface molecule that mediates suppressive signals and induces Foxp3 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

The inhibitory cytokine IL-35 contributes to regulatory T-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Human CD4+ CD25+ Foxp3+ regulatory T cells do not constitutively express IL-35.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Cutting edge: Human regulatory T cells require IL-35 to mediate suppression and infectious tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Human T regulatory cells can use the perforin pathway to cause autologous target cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

CD4+CD25+ regulatory T cells suppress contact hypersensitivity reactions through a CD39, adenosine-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Expression of CD39 by human peripheral blood CD4+ CD25+ T cells denotes a regulatory memory phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Cutting edge: human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

CD40 ligation releases immature dendritic cells from the control of regulatory CD4+CD25+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

CTLA-4 control over Foxp3+ regulatory T cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Expression of FoxP3, a key molecule in CD4CD25 regulatory T cells, in adult T-cell leukaemia/lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Regulatory T cells, tumour immunity and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Differences in tumor regulatory T-cell localization and activation status impact patient outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Human circulating CD4+CD25highFoxp3+ regulatory T cells kill autologous CD8+ but not CD4+ responder cells by Fas-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

CD69+ CD4+ CD25- T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-beta 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Chemokines: a new classification system and their role in immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Chemokines in tumor progression and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Early detection of tumor cells by innate immune cells leads to T(reg) recruitment through CCL22 production by tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Regulatory T-cell compartmentalization and trafficking

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

The relationship of FOXP3 expression and clinicopathological characteristics in adult T-cell leukemia/lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Androgen deprivation boosts prostatic infiltration of cytotoxic and regulatory T lymphocytes and has no effect on disease-free survival in prostate cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Rapid reversal of interleukin-6-dependent epithelial invasion in a mouse model of microbially induced colon carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

The impact of regulatory T cells on carcinogen-induced sarcogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Regulatory T-cell recovery in recipients of haploidentical nonmyeloablative hematopoietic cell transplantation with a humanized anti-CD2 mAb, MEDI-507, with or without fludarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

A novel splice variant of FR4 predominantly expressed in CD4+CD25+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Toll-like receptor control of the adaptive immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Regulation of T cell activation by TLR ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Toll-like receptor 2 signaling modulates the functions of CD4+ CD25+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Dendritic cells and the control of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Immunosuppressive networks in the tumour environment and their therapeutic relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

How tolerogenic dendritic cells induce regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Regulatory T cells and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Deacetylase inhibition promotes the generation and function of regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Taming cancer by inducing immunity via dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Tumor-Infiltrating FOXP3+ T Regulatory Cells Show Strong Prognostic Significance in Colorectal Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Prognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Pretreatment frequency of circulating IL-17+CD4+T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Dendritic Cell Infiltration and Prognosis of Early Stage Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Quantitative and Functional Alterations of Plasmacytoid Dendritic Cells Contribute to Immune Tolerance in Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Quantification of Regulatory T Cells Enables the Identification of High-Risk Breast Cancer Patients and Those at Risk of Late Relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Vitamin A Metabolites Induce Gut-Homing FoxP3+ Regulatory T Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0208-Y

Distribution of CD4+CD25high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer

21 January 2018

1 reference

12 December 2020

Cell interactions in the induction of tolerance: the role of thymic lymphocytes

1 reference

12 December 2020

Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma.

1 reference

12 December 2020

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies

1 reference

12 December 2020

Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients

1 reference

12 December 2020

Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers

1 reference

12 December 2020

Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance

1 reference

12 December 2020

Plasmacytoid dendritic cells resident in human thymus drive natural Treg cell development

1 reference

12 December 2020

Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma

1 reference

12 December 2020

Tumor-infiltrating cytotoxic T cells but not regulatory T cells predict outcome in anal squamous cell carcinoma

1 reference

12 December 2020

Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity

1 reference

12 December 2020

Association of increased levels of heavy-chain ferritin with increased CD4+ CD25+ regulatory T-cell levels in patients with melanoma

1 reference

12 December 2020

VEGFR2 is selectively expressed by FOXP3high CD4+ Treg.

1 reference

12 December 2020

Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases

1 reference

12 December 2020

Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma

1 reference

12 December 2020

Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy

1 reference

12 December 2020

A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients

1 reference

12 December 2020

Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients.

1 reference

12 December 2020

Confirmation of the activity of the interleukin-2 fusion toxin denileukin diftitox against chemorefractory chronic lymphocytic leukemia, including cases with chromosome 17p deletions and without detectable CD25 expression.

1 reference

12 December 2020

The GITR-GITRL interaction: co-stimulation or contrasuppression of regulatory activity?

1 reference

12 December 2020

CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression

1 reference

12 December 2020

Antisense therapeutics for tumor treatment: the TGF-beta2 inhibitor AP 12009 in clinical development against malignant tumors.

1 reference

12 December 2020

Expression of ICOS on human melanoma-infiltrating CD4+CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression

1 reference

12 December 2020

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients

1 reference

12 December 2020

Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma

1 reference

12 December 2020

Increase of regulatory T cells in the peripheral blood of cancer patients.

1 reference

12 December 2020

Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.

1 reference

12 December 2020

Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells

1 reference

12 December 2020

TLR1/TLR2 agonist induces tumor regression by reciprocal modulation of effector and regulatory T cells

1 reference

12 December 2020

Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta

1 reference

12 December 2020

10.1007/S11523-012-0208-Y

Identifiers

DOI

1 reference

26 August 2017

1 reference